From the Desk of the Editor: Volume 3, Issue 3

Welcome to Volume 3, Third issue, of Everyday Urology - Oncology Insights. In this issue, the applicability and utility of SpaceOAR® Hydrogel will be reviewed as well as the trials that led to its regulatory approval. SpaceOAR was designed as a means of diminishing rectal radiation toxicity. With a phase III trial reporting a decrease in acute and long-term rectal toxicity, as well as an enhanced patient, reported quality of life outcomes, SpaceOAR is quickly being adopted as a component of prostate cancer radiotherapy. 

Daniel J. George, MD, and Robert G. Uzzo MD, FACS, review “Nephrectomy in the era of targeted therapy,” focusing on the significance of the CARMENA trial and the decision making involved regarding whether to proceed with a cytoreductive nephrectomy or not for patients with metastatic disease. Importantly, the clinical value and trial data of Sunitinib without cytoreductive nephrectomy is reviewed.

Ashish Kamat, MD, succinctly details within “Blue light cystoscopy: insights on recurrence, progression, and clinical management,” regarding the application of blue light cystoscopy, now recommended by both the American Urologic Association and Society of Urologic Oncology guidelines for cystoscopic evaluation for patients with non-muscle invasive bladder cancer. He analyzes the specific benefits of blue light cystoscopy for bladder cancer surveillance as well as during resection. Over the spring and summer, leading urologists and oncologists have assembled at global meetings in order to share their research as well as to debate the merits of new data and diagnostics and their potential impact upon clinical decision making. These well-known international conferences enable collaboration across geographic boundaries, and thus this edition will further spotlight some timely developments in prostate, bladder and renal cancer research most recently presented.

From the 73rd annual Canadian Urological Association meeting was held in Halifax, Nova Scotia from June 23-24. Geoffrey Gotto, MD, discussion on the use of abiraterone acetate with prednisone in the treatment of metastatic castration-resistant prostate cancer and Sumanta Pal, MD, an overview of treatment updates in renal cell carcinoma, including results of CheckMate 214 and IMmotion 151 are both presented in this edition.

Also, highlights from July’s 2018 Congress of the Mexican Association of Oncological Urology include a talk by Bernardo Gabilondo Pliego, MD on nephron-sparing surgery, as well as a presentation by Daniel Olvera Posada, MD, on emerging biomarkers for prostate cancer detection, are presented.

As always, thank you for reading Everyday Urology - Oncology Insights.

Neal Shore, MD, FACS